TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02705872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h
Description: Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes
Description: Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
Study: NCT03115086

Intervention type: DRUG
Intervention: Cholbam
Description: Cholbam prescribed according to the approved label.

Intervention type: DRUG
Intervention: Cholbam
Description: Cholbam prescribed according to the approved label.
Study: NCT02882412

Intervention type: OTHER
Intervention: observational
Study: NCT03791138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online patient decision aid
Description: An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
Study: NCT02631135

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: BIS values were arranged 40-60 until the end of operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: BIS values were arranged 40-60 until the end of operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 microgram/kg infusion, no changes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: 0.5 mg/kg iv for intubation, no changes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.5 mg/kg iv for intubation, no changes
Study: NCT02794948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese medicine granules (HuYang Yang Kun Formula)
Description: Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dehydroepiandrosterone
Description: The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province.
Study: NCT01025583

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hypotonic oral rehydration solution
Description: 30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
Study: NCT01636024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594
Description: Suspension inhaled via Spira nebuliser
Study: NCT03360344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio 12 inch Tape
Description: Kinesio Tape approximately 12-inch strip will be applied to the dorsal surface of the forearm of the affected side for three-day increments over three weeks of the study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio 4 inch Tape
Description: Kinesio Tape for the control group will be a 4 inch Kinesio Tape applied to the scapular spine for three day increments over three weeks of the study.
Study: NCT01025583

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic oral rehydration solution with Zn and prebiotics
Description: 30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
Study: NCT04245501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretations (CBM-I)
Description: Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interpretation Control Condition (ICC)
Description: Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias.
Study: NCT02891629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeControl device
Description: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeControl device
Description: Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
Study: NCT04240730

Intervention type: PROCEDURE
Intervention: Transvaginal natural orifice endoscopic surgery for endometrial cancer staging
Description: Cases of extreme obese patients with early stage endometrial cancer who underwent v-NOTES
Study: NCT02904707

Intervention type: OTHER
Intervention: Questionary EQ-5D
Description: In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
Study: NCT00751491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosin
Description: Intracoronary Adenosin 50 microg;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 300/600 mg
Study: NCT00580073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
Study: NCT01434303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT01636024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Matching placebo inhaled via Spira nebuliser
Study: NCT02032537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Callmax cream application over affected skin
Description: Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
Study: NCT00649467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Sprinkle Capsules 25 mg
Description: 25mg, single dose applesauce

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Sprinkle Capsules 25 mg
Description: 25mg, single dose applesauce
Study: NCT02931695

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of QT interval duration
Description: ECG to evaluation of QT interval duration

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of QT interval duration
Description: ECG to evaluation of QT interval duration

Intervention type: OTHER
Group type: OTHER
Intervention: circulating sex hormones levels sample
Description: Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).

Intervention type: OTHER
Group type: OTHER
Intervention: circulating sex hormones levels sample
Description: Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
Study: NCT00300469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, 12 weeks, see Arm Description for placebo information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, 12 weeks, see Arm Description for placebo information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, 12 weeks, see Arm Description for placebo information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, 12 weeks, see Arm Description for placebo information
Study: NCT02251054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avatar group
Description: We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Avatar group
Description: We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
Study: NCT01595035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
Study: NCT04257734

Intervention type: OTHER
Intervention: observation
Description: different serum antibodies status
Study: NCT04394975

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Biological : Toripalimab Drug: Axitinib
Description: Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet
Study: NCT03136185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral (capsule) administration according to dose allocation.
Study: NCT01233401

Intervention type: OTHER
Intervention: Survey
Description: Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.

Intervention type: OTHER
Intervention: Survey
Description: Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
Study: NCT02733614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: novel V1a receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT02072317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxel plus raltitrexed
Description: taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxol
Description: taxol 135 mg/m2, every three weeks for a cycle
Study: NCT02949115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 70 mL red beetroot juice
Description: 1x daily intake of 70 mL red beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 70 mL red beetroot juice without nitrate
Description: 1x daily intake of 70 mL red beetroot juice without nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 70 mL placebo drink plus potassium nitrate
Description: 1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 70 mL placebo drink
Description: 1x daily intake of 70 mL placebo control drink
Study: NCT04729088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Description: Intra-anal application performed by the study physician of 2 g of the study drug
Study: NCT03541512

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness + Education
Description: Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health.
Study: NCT01100307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium
Description: Intravitreal injection of 0.3 mg every 6 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: sham injection every 6 weeks
Study: NCT02241746

Intervention type: OTHER
Intervention: no intervention
Study: NCT00441558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin
Description: flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
Study: NCT01247220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab 0.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab 0.5 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Laser
Description: Angiography-directed peripheral laser
Study: NCT00918476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filibuvir + Oral Contraceptives
Description: This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
Study: NCT02572830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Bilateral Eye Movements
Description: Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Undelayed Bilateral Eye Movement
Description: Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
Study: NCT02918188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
Study: NCT02310971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVac
Description: Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
Study: NCT01899404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 18-FDG PET/CT, DWI, DCE-MRI
Description: All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
Study: NCT00435032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early appendectomy
Description: Appendectomy within 24 hours of admission

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interval appendectomy
Description: Initial antibiotic treatment followed by appendectomy at 6-8 weeks
Study: NCT02627131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study: NCT03838172

Intervention type: OTHER
Intervention: Family impact scale
Description: The family Impact Scale (FIS) will be completed by the parents
Study: NCT00916123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg per day starting on cycle 1, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg per day starting on cycle 1, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg per day starting on cycle 1, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg per day starting on cycle 1, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg per day starting on cycle 1, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
Study: NCT03360344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cock up Splint and Lumbrical exercises
Description: A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.